Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more
Aptorum Group Ltd Class A (APM) - Net Assets
Latest net assets as of September 2025: $13.77 Million USD
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has net assets worth $13.77 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.10 Million) and total liabilities ($4.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.77 Million |
| % of Total Assets | 76.05% |
| Annual Growth Rate | -9.03% |
| 5-Year Change | -69.13% |
| 10-Year Change | N/A |
| Growth Volatility | 73.13 |
Aptorum Group Ltd Class A - Net Assets Trend (2016–2024)
This chart illustrates how Aptorum Group Ltd Class A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aptorum Group Ltd Class A (2016–2024)
The table below shows the annual net assets of Aptorum Group Ltd Class A from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $11.78 Million | -23.44% |
| 2023-12-31 | $15.38 Million | +96.38% |
| 2022-12-31 | $7.83 Million | -55.25% |
| 2021-12-31 | $17.51 Million | -54.12% |
| 2020-12-31 | $38.15 Million | +156.89% |
| 2019-12-31 | $14.85 Million | -54.65% |
| 2018-12-31 | $32.75 Million | +8.33% |
| 2017-12-31 | $30.23 Million | +20.36% |
| 2016-12-31 | $25.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aptorum Group Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2361.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.00 | 0.00% |
| Other Comprehensive Income | $89.16K | 0.42% |
| Other Components | $93.47 Million | 442.29% |
| Total Equity | $21.13 Million | 100.00% |
Aptorum Group Ltd Class A Competitors by Market Cap
The table below lists competitors of Aptorum Group Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
P.C.B Tec
TA:PCBT
|
$3.08 Million |
|
Yummy Town Cayman Holdings
TWO:2726
|
$3.08 Million |
|
Recharge Resources Ltd.
PINK:RECHF
|
$3.08 Million |
|
Miraculum SA
WAR:MIR
|
$3.08 Million |
|
Alderan Resources Ltd
AU:AL8
|
$3.07 Million |
|
Ho Wah Genting Bhd
KLSE:9601
|
$3.07 Million |
|
Tarjar Xairo Socimi SA
MC:YTAR
|
$3.07 Million |
|
Supply@Me Capital PLC
LSE:SYME
|
$3.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aptorum Group Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 24,846,236 to 21,134,514, a change of -3,711,722 (-14.9%).
- Net loss of 4,268,000 reduced equity.
- Other comprehensive income increased equity by 99,785.
- Other factors increased equity by 456,493.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.27 Million | -20.19% |
| Other Comprehensive Income | $99.78K | +0.47% |
| Other Changes | $456.49K | +2.16% |
| Total Change | $- | -14.94% |
Book Value vs Market Value Analysis
This analysis compares Aptorum Group Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.08x to 0.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $10.04 | $0.79 | x |
| 2018-12-31 | $11.86 | $0.79 | x |
| 2019-12-31 | $5.64 | $0.79 | x |
| 2020-12-31 | $13.27 | $0.79 | x |
| 2021-12-31 | $6.74 | $0.79 | x |
| 2022-12-31 | $4.40 | $0.79 | x |
| 2023-12-31 | $5.50 | $0.79 | x |
| 2024-12-31 | $3.88 | $0.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aptorum Group Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.76x
- Recent ROE (-20.19%) is above the historical average (-39.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -8.50% | 0.00% | 0.00x | 1.01x | $-4.65 Million |
| 2017 | -8.42% | 0.00% | 0.00x | 1.04x | $-5.57 Million |
| 2018 | -44.79% | -3868.04% | 0.01x | 1.36x | $-18.14 Million |
| 2019 | -114.22% | -3491.81% | 0.02x | 1.46x | $-20.32 Million |
| 2020 | 16.89% | 775.31% | 0.02x | 1.06x | $2.88 Million |
| 2021 | -106.10% | -1624.38% | 0.07x | 0.93x | $-27.41 Million |
| 2022 | -62.37% | -756.17% | 0.06x | 1.33x | $-11.37 Million |
| 2023 | -11.37% | -654.88% | 0.02x | 0.83x | $-5.31 Million |
| 2024 | -20.19% | 0.00% | 0.00x | 0.76x | $-6.38 Million |
Industry Comparison
This section compares Aptorum Group Ltd Class A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aptorum Group Ltd Class A (APM) | $13.77 Million | -8.50% | 0.31x | $3.07 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |